NKG2D signaling certifies effector CD8 T cells for memory formationCynthia Pérez, José A. Guevara-Patiño|Journal for ImmunoTherapy of Cancer|2019Cited by 32
EGFR Inhibition by Cetuximab Modulates Hypoxia and IFN Response Genes in Head and Neck Squamous Cell CarcinomaRitu Chaudhary, Christine H. Chung, Robbert J.C. Slebos et al.|Cancer Research Communications|2023Cited by 14
Clinical significance of peripheral T-cell repertoire in head and neck squamous cell carcinoma treated with cetuximab and nivolumabXuefeng Wang, Christine H. Chung, Tingyi Li et al.|Cancer Immunology Immunotherapy|2025Cited by 10
Long-term Survival and Molecular Biomarker Evaluation of a Phase II Cetuximab and Nivolumab Clinical Trial in Recurrent/Metastatic Head and Neck CancerRitu Chaudhary, Christine H. Chung, Graydon Moorhead et al.|Clinical Cancer Research|2025Cited by 3
Phase I Trial of Ex Vivo Expanded Donor Gamma Delta T Cell Immunotherapy to Prevent Acute Myeloid Leukemia Relapse after Allogeneic TransplantationNelli Bejanyan, Marco L. Davila, Hany Elmariah et al.|Blood|2024Cited by 2